Research Square
October 29, 2026
Jiaojian Wang, Jin Chen, Wenjie Sun et al.
preprint
Abstract Psilocybin holds strong therapeutic promise for treating major depressive disorder. However, the cellular and molecular substrates underlying its action have not been fully elucidated, especially in the primate brain. We combined multimodal MRI, magnetic resonance spectroscopy (MRS), cerebrospinal fluid (CSF) proteomics and metabolomics, and single-nucleus RNA sequencing (snRNA-seq) to...
National Science Review
September 5, 2025
Huoqing Luo, Ming Chen, Yingjie Ning et al.
1 citation
-methyl-d-aspartate receptor (NMDAR) blockade is crucial for the rapid antidepressant effects of ketamine, the involvement of other mechanisms remains contentious, particularly regarding the role of serotonin, a key neurotransmitter in the target of traditional antidepressants. Here, we demonstrate that ketamine elevates serotonin levels by inhibiting the serotonin transporter (SERT). A...
Cell Reports
January 28, 2025
Yue Hu, Yifan Feng, Huoqing Luo et al.
6 citations
Dissociation, characterized by altered consciousness and perception, underlies multiple mental disorders, but the specific neuronal subtypes involved remain elusive. In mice, we find that dissociation-inducing doses of ketamine significantly inhibit retrosplenial cortex (RSC) parvalbumin interneurons (PV-INs), enhancing delta oscillations (1-3 Hz) and delta-gamma phase-amplitude coupling (δ-γ...
British Journal of Anaesthesia
December 1, 2023
Wenying Duan, Kang Peng, Hui-Min Qin et al.
BACKGROUND Delayed emergence from general anaesthesia poses a significant perioperative safety hazard. Subanaesthetic doses of ketamine not only deepen anaesthesia but also accelerate recovery from isoflurane anaesthesia; however, the mechanisms underlying this phenomenon remain elusive. Esketamine exhibits a more potent receptor affinity and fewer adverse effects than ketamine and exhibits...